Barclays lowered the firm’s price target on Tvardi Therapeutics (TVRD) to $4 from $5 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post the Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
- Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
- Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
- Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital